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Introduction
Obtaining T cell receptor repertoires specific for cancer
antigens in individuals is of great significance in terms
of their relationships with the clinical courses and thera-
peutic application such as adoptive transfer. However,
full analyses of T cell receptor (TCR) sequences have
been difficult because of the inefficiency of T cell clon-
ing, heterogeneity of T cells or the heterodimeric struc-
tures of TCRs. Here, we revealed complete landscapes
of cancer antigen-specific TCRs using a novel TCR
cloning system; hTEC10 (human TCR efficient cloning
within 10 days) [1].
Methods
Fifteen patients were chosen from the participants of
the Phase I clinical trial using HLA-A*2402-restricted
a-fetoprotein (AFP)-derived peptide vaccine for
advanced hepatocellular carcinoma (HCC). The pep-
tide-specific cytotoxic lymphocytes (CTLs) were
detected and sorted as single cells from the patients’
peripheral mononuclear cells (PBMCs) after in vitro
stimulation. cDNAs of paired TCR chains were ampli-
fied from the single cells, cloned into retroviral vectors,
and transduced in the T cell strain or PBMCs. The
avidities of the obtained TCRs were evaluated by com-
paring antigen-specific cytotoxicities. This system was
also applied to the healthy controls and the partici-
pants of the Phase I clinical trial of human telomerase
reverse transcriptase (hTERT)-derived peptide vaccine
for prevention of HCC recurrence after radiofrequency
ablation (RFA) therapy.
Results and discussion
AFP-specific CTLs were induced in 4 patients whose
clinical responses were CR (no recurrence on day
1,336), long SD (TTP, 812 days), SD (91 days) and PD
(46 days), respectively (long SD is defined as SD over 6
months). Totally, 347 specific TCR clones that consisted
of 10 kinds of TCR gene rearrangements (3 from the
CR patient; 4 from the long SD patient; 2 from the SD
patient and 1 from the PD patient) were amplified. The
TCRs obtained from the CR patient and the long SD
patient possessed higher avidities than that from the SD
patient, the PD patient and the healthy controls without
HCC. Similarly, we could obtain highly reactive 122
TCR clones consist of 10 different gene arrangements
from 3 patients who were treated with hTERT vaccine
and prevented from the recurrence until 24 weeks after
RFA. These results indicated that the inductions of
TCRs with high avidities reflected the good clinical
responses, and high-avidity TCR might be retrieved
from vaccinated patients with good clinical responses,
not from patients with poor responses or healthy
individuals.
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